Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATG-010 plus low-dose dexamethasone in relapsed/refractory multiple myeloma
CTR20190858Phase 2Completed
- Sponsor
- Catalent
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selinexor in multiple myeloma (MM), sponsored by Catalent. Started Jun 2019; status: completed.
02
Drugs
selinexor
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20190858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190858.